CYP2D6 and hyperprolactinemia: As a consequence, ASD children who are CYP2D6 PMs or IMs might be at higher risk of developing hyperprolactinemia when treated with risperidone (Puangpetch et al., 2016; de Leon, 2020; Soria-Chacartegui et al., 2021; Biswas et al., 2022b).